

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 May 2012 (18.05.2012)

(10) International Publication Number
WO 2012/065022 A2

(51) International Patent Classification:
C07D 487/10 (2006.01) **A61P 35/00** (2006.01)
A61K 31/407 (2006.01)

(21) International Application Number:
PCT/US2011/060300

(22) International Filing Date:
11 November 2011 (11.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/413,094 12 November 2010 (12.11.2010) US
61/451,958 11 March 2011 (11.03.2011) US
61/451,968 11 March 2011 (11.03.2011) US
61/470,992 1 April 2011 (01.04.2011) US

(71) Applicants (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF MICHIGAN** [US/US]; 1600 Huron Parkway, Second Floor, Ann Arbor, Michigan 48109 (US). **ASCENTA THERAPEUTICS, INC.** [US/US]; 101 Lindenwood Drive, Suite 405, Malvern, Pennsylvania 19355 (US). **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Shaomeng** [US/US]; 9343 Yorkshire Drive, Saline, Michigan 48176 (US). **ZHAO, Yujun** [CN/US]; 3535 GreenBrier Blvd., Apartment 58B, Ann Arbor, Michigan 48105 (US). **SUN, Wei** [CN/US]; 2825 Arrowwood Trail, Ann Arbor, Michigan 48105 (US). **KUMAR, Sanjeev** [US/US]; 3310 Alpine Drive, Ann Arbor, Michigan 48108 (US). **LEOPOLD, Lance** [US/US]; 1441 Catlin Way, Dresher, Pennsylvania 19025 (US). **DEBUSSCHE, Laurent** [FR/FR]; c/o Sanofi, 174 avenue de France, F-75013 Paris

(FR). **BARRIERE, Cedric** [FR/FR]; c/o Sanofi, 174 avenue de France, F-75013 Paris (FR). **CARRY, Jean-Christophe** [FR/FR]; c/o Sanofi, 174 avenue de France, F-75013 Paris (FR). **AMANING, Kwame** [GB/FR]; c/o Sanofi, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **GOETZ, Robert A.**; Casimir Jones SC, 2275 Deming Way, Suite 310, Middleton, WI 53562 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SPIRO-OXINDOLE MDM2 ANTAGONISTS

(57) Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.



WO 2012/065022 A2